Trial 0C-20-19


A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Xiomara Menendez, R.N., Jessica Levano, Coordinator, Khatchik Karakozian, D.M., Maura Fernandez, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.